Flossbach Von Storch SE Sells 310,639 Shares of IDEXX Laboratories, Inc. $IDXX

Flossbach Von Storch SE lessened its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 56.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 241,125 shares of the company’s stock after selling 310,639 shares during the period. Flossbach Von Storch SE owned about 0.30% of IDEXX Laboratories worth $129,325,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of IDXX. Bank of New York Mellon Corp grew its position in IDEXX Laboratories by 156.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,451,390 shares of the company’s stock valued at $778,439,000 after acquiring an additional 884,808 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of IDEXX Laboratories by 71.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,988,912 shares of the company’s stock valued at $835,244,000 after purchasing an additional 825,965 shares during the period. Select Equity Group L.P. bought a new position in shares of IDEXX Laboratories in the first quarter worth about $194,834,000. Nuveen LLC bought a new position in shares of IDEXX Laboratories in the first quarter worth about $179,784,000. Finally, Durable Capital Partners LP purchased a new position in IDEXX Laboratories in the 1st quarter worth about $153,180,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, EVP Nimrata Hunt sold 1,200 shares of the company’s stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $656.53, for a total transaction of $787,836.00. Following the transaction, the executive vice president directly owned 16,807 shares of the company’s stock, valued at $11,034,299.71. This represents a 6.66% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director M Anne Szostak sold 2,187 shares of the stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $647.33, for a total value of $1,415,710.71. Following the completion of the sale, the director owned 262 shares of the company’s stock, valued at approximately $169,600.46. This trade represents a 89.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 3,793 shares of company stock worth $2,467,430. Insiders own 0.98% of the company’s stock.

IDEXX Laboratories Price Performance

IDXX opened at $708.45 on Friday. The firm has a market capitalization of $56.57 billion, a PE ratio of 58.99, a price-to-earnings-growth ratio of 4.06 and a beta of 1.62. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79. The business’s 50-day moving average is $645.28 and its two-hundred day moving average is $579.33. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $735.00.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Monday, November 3rd. The company reported $3.40 earnings per share for the quarter, beating analysts’ consensus estimates of $3.14 by $0.26. The business had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The company’s revenue was up 13.3% compared to the same quarter last year. During the same period last year, the business earned $2.80 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently issued reports on IDXX. Morgan Stanley increased their price objective on IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a research note on Tuesday. Jefferies Financial Group reissued a “buy” rating and set a $830.00 price target on shares of IDEXX Laboratories in a research report on Tuesday. Stifel Nicolaus set a $775.00 price objective on IDEXX Laboratories in a report on Monday, November 3rd. UBS Group upped their price objective on shares of IDEXX Laboratories from $710.00 to $750.00 and gave the stock a “neutral” rating in a research note on Tuesday. Finally, Wall Street Zen raised shares of IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research report on Saturday. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $730.50.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.